Science Applications Intl
SAIC Nasdaq· Diversified Support Services
Last close · Oct 26, 2026
$148.51
KIRA · Stoqly’s AI analyst, in plain words
- Science Applications Intl had $7.3B of revenue in fiscal 2026, down 2.9% on the year before. Over five years, revenue changed +0.6% a year on average.
- Its operating margin was 7.2%, down 0.4 pts: of every 100 in sales, about 7 is left after running the business.
- Science Applications Intl made $358M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 10.6% a year.
- Free cash flow was $577M in fiscal 2026, 8.0% of revenue.
- Science Applications Intl returned $515M to shareholders in fiscal 2026, 89% of free cash flow. The diluted share count fell 7.9%.
- Science Applications Intl owes $2.3B more than it holds in cash, about 4.2 years of operating profit.
Market cap
$6.4B
P/E
17.3x
Revenue
$7.3B
Net income
$358M
Free cash flow
$577M
Operating margin
7.2%
Science Applications Intl in 30 seconds · fiscal 2026
Are sales growing?
−2.9%
No. Sales fell 2.9% last year.
Does it make a profit?
4.9%
A little. It keeps 4.9% of every sale as profit.
Does profit turn into cash?
8.0%
Partly. 8.0% of sales ends up as free cash.
Is debt under control?
4.2x
Heavy. Repaying its debt would take 4.2 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
17.3x
One share costs 17.3 times its yearly profit per share. Typical for its sector: 26.0x.
What Science Applications Intl does
No business description yet.
- Fiscal year ends
- January 30, 2026
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Science Applications International Corporation
- CIK
- 0001571123
Science Applications Intl · SAIC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $7.4B | $7.7B | $7.4B | $7.5B | $7.3B |
| Revenue growth | 4.8% | 4.2% | −3.4% | 0.5% | −2.9% |
| Gross margin | 11.6% | 11.5% | 11.7% | 11.9% | 12.0% |
| Operating margin | 6.3% | 6.5% | 10.0% | 7.5% | 7.2% |
| Net income | $277M | $300M | $477M | $362M | $358M |
| Net margin | 3.8% | 3.9% | 6.4% | 4.8% | 4.9% |
| Diluted EPS | $4.77 | $5.38 | $8.88 | $7.17 | $7.70 |
| Cash | |||||
| Cash from operations | $518M | $532M | $396M | $494M | $609M |
| Capital expenditure | $36.0M | $25.0M | $27.0M | $36.0M | $32.0M |
| Free cash flow | $482M | $507M | $369M | $458M | $577M |
| FCF margin | 6.5% | 6.6% | 5.0% | 6.1% | 8.0% |
| Dividends paid | $86.0M | $83.0M | $79.0M | $75.0M | $70.0M |
| Share buybacks | $226M | $267M | $382M | $558M | $445M |
| Share count change | −1.0% | −4.0% | −3.8% | −6.0% | −7.9% |
| Debt and strength | |||||
| Cash and short-term investments | $106M | $109M | $94.0M | $56.0M | $182M |
| Debt incl. finance leases | $2.5B | $2.4B | $2.1B | $2.2B | $2.5B |
| Shareholders' equity | $1.6B | $1.7B | $1.8B | $1.6B | $1.5B |
| Net debt / EBITDA | 4.8x | 4.3x | 2.6x | 3.7x | 4.2x |
| Current ratio | 0.9x | 1.1x | 1.0x | 0.8x | 1.2x |
| Interest coverage | 4.4x | 4.2x | 5.9x | 4.7x | 5.2x |
| Returns and quality | |||||
| Return on capital | 9.1% | 10.1% | 14.7% | 12.7% | 12.8% |
| Return on equity | 17.5% | 18.1% | 27.4% | 21.5% | 23.3% |
| Piotroski F-score | 7 | 8 | 7 | 6 | 7 |
| Altman Z'' | 1.3 | 1.8 | 2.3 | 1.8 | 2.2 |
Insiders bought, 12 months
$0.5M
6 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Science Applications Intl · SAIC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Science Applications Intl SAIC | $6.4B | −2.9% | 7.2% | 8.0% | 12.8% | 17.3x | 7 |
| KBR KBR | $5.1B | 1.0% | 10.0% | 6.6% | 15.8% | 12.0x | 7 |
| CACI International CACI | $14.8B | 10.9% | 9.6% | 8.2% | 8.8% | 27.3x | 5 |
| Cintas CTAS | $91.3B | 8.9% | 23.1% | 16.7% | 31.7% | 44.6x | 8 |
| Copart CPRT | $27.9B | 0.4% | 35.4% | 27.2% | 19.6% | — | 4 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $148.51 a share, the company is worth $6.4B: 17.3 times its earnings of the last four quarters.
Science Applications Intl grew sales faster than 0 of its 4 similar companies. Its P/E is higher than 1 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001571123). Data updated October 18, 2026. For information only — not investment advice. Check the original filings before relying on any figure.